|
T6321 |
Tofacitinib
|
Tasocitinib,CP-690550 |
ROCK
,
Apoptosis
,
JAK
,
Src
|
|
Tofacitinib (Tasocitinib) is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis. |
|
T2398 |
Tofacitinib Citrate
|
CP-690550 citrate,Tasocitinib citrate,Tofacitinib (CP-690550) Citrate |
Apoptosis
,
Influenza Virus
,
JAK
,
Antibacterial
,
Antifungal
|
|
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM). |
|
T37638 |
Tofacitinib metabolite-1
|
|
|
|
Tofacitinib metabolite-1, a derivative of Tofacitinib, which is a JAK inhibitor, is employed in studies focused on the pharmacokinetics and metabolism of tofacitinib[1][2]. |
|
T13426L |
(3S,4S)-Tofacitinib
|
|
Others
|
|
(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor. |
|
T13426 |
(3R,4S)-Tofacitinib
|
|
Others
|
|
(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM). |
|
T13427 |
(3S,4R)-Tofacitinib
|
|
Others
|
|
(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM). |
|
T70168 |
Tofacitinib HCl
|
|
|
|
Tofacitinib, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes ... |
|
T69958 |
Tofacitinib maleate
|
|
|
|
Tofacitinib, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes ... |
|
T72406 |
Tofacitinib Prodrug-1
|
|
|
|
Tofacitinib Prodrug-1 is an effective and oral active prodrug to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib Prodrug-1 can effectively attenuate the oxazolone-induced colitis in mice model with low ... |
|
T31074 |
CP-690550A
|
Tofacitinib metabolite M2,CP-690,550A,UNII-Q7ZOK859UK |
|
|
Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases. |
|
T69957 |
Quoromycin
|
|
|
|
Quoromycin is a novel antivirulence agent against Vibrio vulnificus, inhibiting the quorum-sensing signaling pathway by controlling the DNA-binding affinity of SmcR and thus effectively alleviating the virulence of V. vu... |
|
T70167 |
BP-5-087
|
|
|
|
BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia. |
